Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. - Wikidata - wikimedia - TriplyDB

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines.

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines.

http://www.wikidata.org/entity/Q36617317

about

Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer.Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.Novel combination chemotherapy in the treatment of non-small cell lung cancer.A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.The additive damage model: a mathematical model for cellular responses to drug combinations.A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.

P2860

Q33716280-720FBA03-A1B0-4518-BA0E-3BBA766AECD7 Q33718820-B68D5B1A-4201-44A9-A1BF-AB6BA1A233D4 Q34181910-05CAE6D7-D91A-435C-88E4-82F380BA22C7 Q35817502-F3A54349-B42E-47B5-9A74-B78905F3DF97 Q39683758-009EB1ED-029E-41D8-8C3B-C4F35E8EE1F5 Q40718608-6D486E60-A670-468F-8CA7-A01324C0E5F1 Q43067222-69E74268-0637-47D6-BC52-1DE18BC2E4E3 Q46435201-72B452D4-37B4-484E-88D4-A239A4824004 Q52136435-DF64AC29-BE18-4BC8-85E8-EA82C30F8B5F

P2860

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines.

http://www.wikidata.org/entity/Q36617317

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Additive and supra-additive cy ...... ovarian carcinoma cell lines.

@ast

Additive and supra-additive cy ...... ovarian carcinoma cell lines.

@en

type

label

Additive and supra-additive cy ...... ovarian carcinoma cell lines.

@ast

Additive and supra-additive cy ...... ovarian carcinoma cell lines.

@en

prefLabel

Additive and supra-additive cy ...... ovarian carcinoma cell lines.

@ast

Additive and supra-additive cy ...... ovarian carcinoma cell lines.

@en

P1433

Q36617317-2BDD1A9D-3D9D-429D-A63D-76C3C1B8B31E

P1476

Q36617317-E1C1912E-4BCA-4BF8-AA98-66F0C613F5E5

P2093

Q36617317-0FEA2C07-C683-4ADF-BC82-59730E14FC8F

Q36617317-15C6E962-7AE5-43B6-BADF-92DFB8A170DF

Q36617317-D82F856E-CF5F-49B9-B56C-9257DE7B1D95

Q36617317-E15DFB68-70B3-4670-97A1-66E3280B7B62

Q36617317-EF5CD213-0C18-40E6-B5B1-B2831D998187

P2860

Q36617317-1DEB079C-7EC6-4493-926D-FBDFC017BE73

Q36617317-252FD335-95DD-4DCD-81AE-7B6BACFAD701

Q36617317-427256BE-279F-4B7D-97C6-446E7FE2AE5B

Q36617317-5E1AB307-5ABA-4C13-884D-BC5302C11872

Q36617317-6D7B0152-065F-44A4-803D-38FF07136403

Q36617317-7B10D9D0-18D6-40B6-929B-564FB7B70086

Q36617317-7CE3F8DE-FF63-41B9-BF83-34437E816BD2

Q36617317-7FED7B6C-4DA3-4F05-B139-649BF622BE97

Q36617317-891AE224-A012-40EF-B3A8-C635F624A359

Q36617317-8A4203E7-534C-4EF6-8DBA-B2F82094BB15

P2888

Q36617317-BA5E5182-BE3F-4CE4-B055-255E5B2F1548

P304

Q36617317-FB64AA39-6788-4F46-A94D-46372E5BF3F2

P31

Q36617317-637EF4F5-8607-4BBB-B5BB-90F3CE98B664

P356

Q36617317-001F3113-18AD-4F98-A146-E10978A3D487

P407

Q36617317-8817A431-9D25-44A0-94F9-772127A76FFA

P433

Q36617317-03078D2F-4663-4A0E-A0AD-D111F4864BB7

P478

Q36617317-63C519B5-8E15-4F76-9D51-86473E546505

P577

Q36617317-3D3AAA5D-E5D1-454D-BA5A-82B55F447FD8

P5875

Q36617317-E90116CD-B444-4E5F-AFC7-BD5796001858

P698

Q36617317-2D091527-46A2-4E41-9C73-214C7FFD46E1

P932

Q36617317-A79B3A6C-0B61-4675-A8CF-863F77004865

P356

P1433

British Journal of Cancer

P1476

Additive and supra-additive cy ...... ovarian carcinoma cell lines.

@en

P2093

H Helenius

http://www.w3.org/2001/XMLSchema#string

J Kulmala

http://www.w3.org/2001/XMLSchema#string

P Engblom

http://www.w3.org/2001/XMLSchema#string

S Grènman

http://www.w3.org/2001/XMLSchema#string

V Rantanen

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro

Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.

Chemotherapy in ovarian carcinoma: present role and future prospects.

Preclinical evaluation of docetaxel (Taxotere).

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Current dosage and schedule issues in the development of paclitaxel (Taxol).

Docetaxel (Taxotere) in combination: a step forward.

Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay.

Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.

Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

P2888

P304

286-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6690046

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

1999-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13401567

http://www.w3.org/2001/XMLSchema#string

P698

9888470

http://www.w3.org/2001/XMLSchema#string

P932

2362186

http://www.w3.org/2001/XMLSchema#string